Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management

Download All
In this online program, experts discuss how to best use BTK inhibitors to enhance patient care across multiple B-cell malignancies. Watch the on-demand Webcast and download the slides from a dynamic CCO symposium in Orlando, and read expert commentaries on the new data to learn more about how and when to use BTK-targeted regimens for your patients with cancer.
Ian W. Flinn, MD, PhD
Program Director
Jan A. Burger, MD, PhD
Alexey Danilov, MD
John Pagel Headshot
John Pagel, MD, PhD

On-Demand Webcast

Learn how experts leverage BTK inhibitors for optimal management of patients with MCL, CLL, and other B-cell malignancies in this CME-certified, on-demand Webcast of a dynamic CCO symposium at ASH 2019.

Ian W. Flinn, MD, PhD
Program Director Jan A. Burger, MD, PhD Alexey Danilov, MD John Pagel Headshot John Pagel, MD, PhD Physicians: maximum of 2.75 AMA PRA Category 1 Credits™ Released: February 4, 2020 Expired: No longer available for credit
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings